Vincent Ribrag, MD PhD, is medical oncologist by training and is currently working at Institut Gustave Roussy as head of the Hematology department and head of the early drug development tumor board. He has developed and is still in charge of the hematology phase I track at the early drug department. He led more than 50 phase I trials during the last 10 years and started the cell-therapy phase II program in solid tumors with JP Armand. Among numerous experimental activities, he created a translational hematology laboratory and was associated with different INSERM research units the last years. He is currently affiliated to INSERM UMR-1170 led by Dr Olivier Bernard entitled “transcriptional control and epigenetics of malignant hematopoiesis”. He has been involved in over 550 publications and is member of several international cancer societies, namely the American Association of clinical Oncology (ASCO) and the American Society of Hematology (ASH). He is included in the Scientific and Administrative Committees of LYSA network and CALYM Institut Carnot, and is also Head of early trials of the European Mantle Cell Lymphoma study group. Dr Ribrag’s strong expertise in both early clinical development of innovative therapies and translational cancer research makes in a strong asset for PEGASCY.